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Angptl4 Upregulates Cholesterol Synthesis in Liver via
Inhibition of LPL- and HL-Dependent Hepatic
Cholesterol Uptake
Laeticia Lichtenstein, Jimmy F.P. Berbe´e, Susan J. van Dijk, Ko Willems van Dijk, Andre´ Bensadoun,
Ido P. Kema, Peter J. Voshol, Michael Mu¨ller, Patrick C.N. Rensen, Sander Kersten
Background—Dysregulation of plasma lipoprotein levels may increase the risk for atherosclerosis. Recently, angiopoietin-
like protein 4, also known as fasting-induced adipose factor Fiaf, was uncovered as a novel modulator of plasma
lipoprotein metabolism. Here we take advantage of the fasting-dependent phenotype of Angptl4-transgenic (Angptl4-
Tg) mice to better characterize the metabolic function of Angptl4.
Methods and Results—In 24-hour fasted mice, Angptl4 overexpression increased plasma triglycerides (TG) by 24-fold,
which was attributable to elevated VLDL-, IDL/LDL- and HDL-TG content. Angptl4 overexpression decreased
post-heparin LPL activity by stimulating conversion of endothelial-bound LPL dimers to circulating LPL monomers. In
fasted but not fed state, Angptl4 overexpression severely impaired LPL-dependent plasma TG and cholesteryl ester
clearance and subsequent uptake of fatty acids and cholesterol into tissues. Consequently, hepatic cholesterol content
was significantly decreased, leading to universal upregulation of cholesterol and fatty acid synthesis pathways and
increased rate of cholesterol synthesis.
Conclusions—The hypertriglyceridemic effect of Angptl4 is attributable to inhibition of LPL-dependent VLDL lipolysis
by converting LPL dimers to monomers, and Angptl4 upregulates cholesterol synthesis in liver secondary to inhibition
of LPL- and HL-dependent hepatic cholesterol uptake. (Arterioscler Thromb Vasc Biol. 2007;27:2420-2427.)
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The enzyme lipoprotein lipase (LPL) plays a pivotal rolein the regulation of plasma TG levels. By catalyzing the
irreversible hydrolysis of plasma TG, LPL promotes the
clearance of TG-rich lipoproteins from plasma. After synthe-
sis in adipocytes and (cardio)myocytes, LPL protein is
translocated to luminal endothelial cell surfaces where it is
attached via heparan sulfate proteoglycans (HSPG).1
As LPL is rate-limiting for clearance of TG-rich lipopro-
teins, the activity of LPL is carefully regulated via numerous
mechanisms. At the level of gene transcription, LPL is
upregulated by the transcription factors peroxisome prolifera-
tors activated receptor (PPAR) in adipose tissue and by liver
X receptor (LXR) and PPAR in liver.2 In accordance with
the fat storage function of adipose tissue, expression of LPL
in adipose tissue peaks in the postprandial state, whereas in
skeletal muscle expression of LPL is highest in the postab-
sorptive state.3 LPL is also extensively regulated at the level
of enzyme activity. Indeed, several modulators of LPL
activity are known, including apolipoproteins Apoc3, Apoc2,
Apoc1, and Apoa5.4–6 In addition to apolipoproteins, recently
it became evident that 2 proteins belonging to the family of
angiopoietin-like proteins (Angptls), Angptl3 and Angptl4,
can modulate LPL activity.7
In contrast to Angptl4, Angptl3 is produced exclusively in
liver and is a target of LXR. It was shown that a mutation in
the gene for Angptl3 is responsible for low plasma TG levels
in KK/Snk mice, a mutant strain of KK obese mice.8 The
stimulatory effect of Angptl3 on fasting plasma TG can be
attributed to suppression of VLDL clearance via LPL
inhibition.9
Angptl4, also known as fasting-induced adipose factor
Fiaf, was discovered by screening for genes responsive to
PPAR and , which serve as the molecular targets for the
hypolipidemic fibrate and the insulin sensitizing thiazo-
lidinedione drugs, respectively.10,11 Angptl4 has a molecular
mass of about 50 kDa, is secreted into the blood, and may act
in a paracrine and endocrine fashion. In humans, Angptl4
mRNA expression is highest in liver, followed by adipose
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tissue, whereas in mice the order is reversed.12 The abun-
dance of Angptl4 in blood plasma is increased by fasting and
decreased by feeding a high fat diet, suggesting a potential
role in lipid metabolism.10 Evidence linking Angptl4 to
regulation of plasma lipoproteins was provided by the dem-
onstration that injecting mice with recombinant Angptl4
protein significantly increased plasma TG concentrations,
possibly by inhibiting LPL activity.13 Subsequent studies
using various models of in vivo Angptl4 overexpression or
inactivation have confirmed the stimulatory effect of Angptl4
on plasma TG levels via a mechanism independent of
VLDL-TG secretion.14–18 The hypertriglyceridemic effect of
Angptl4 may be modulated by formation of higher order
oligomers as well as by proteolytic processing.15 Recent in
vitro studies suggest that Angptl4 inhibits LPL by promoting
the conversion of catalytically active LPL dimers into cata-
lytically inactive LPL monomers, thereby permanently inac-
tivating LPL.19 Currently, it is unclear whether this mecha-
nism of LPL inhibition also occurs in vivo.
It has been suggested that in addition to lipid metabolism,
Angptl4 also governs glucose homeostasis. Adenoviral-
mediated Angptl4 overexpression markedly reduced plasma
glucose and improved glucose tolerance.16 However, studies
with Angptl4 knockout mice failed to reveal an effect of
Angptl4 on glucose homeostasis.17 Thus, the effects of
Angptl4 on glucose homeostasis remain ambiguous.
A partial analysis of the phenotype of our Angptl4 trans-
genic mouse model has been previously published.18 The
transgenic mice were generated using the full-length mouse
genomic Angptl4 sequence containing the regulatory regions
mediating responsiveness to PPARs. As a result, Angptl4
overexpression is amplified by fasting. Here we take advan-
tage of the sensitivity of Angptl4-Tg mice to fasting to better
characterize the metabolic function of Angptl4 and address:
(1) the in vivo molecular mechanisms underlying its hyper-
triglyceridemic effect, (2) the consequence of LPL-inhibition
for hepatic cholesterol metabolism and cholesterol-dependent
hepatic gene regulation, and (3) the effect of Angptl4 on
glucose homeostasis.
Methods
For detailed methods, please see the supplemental materials (avail-
able online at http://atvb.ahajournals.org).20–26
Animals
The Angptl4-transgenic mice on FVB background have been previ-
ously described.18 Only male mice were used. All animal experi-
ments were approved by the animal experimentation committee of
Wageningen University.
Results
The Angptl4 transgenic (Angptl4-Tg) mice used in this
manuscript have been previously described.18 While in the
fed state Angptl4-Tg mice show only mildly increased
Angptl4 expression in skeletal muscle, heart, white adipose
tissue (WAT), and brown adipose tissue (BAT), in the
24-hour fasted state dramatic Angptl4 overexpression is
observed in all tissues examined, including liver (supplemen-
tal Figure I).
To examine the effect of Angptl4 overexpression on lipid
metabolism, several plasma parameters were determined.
Although already in the fed state Angptl4 overexpression
significantly increased plasma levels of free fatty acids
(FFA), glycerol, and TG, the increase was much more
pronounced in the 24-hour fasted state (supplemental Table
I). During the course of fasting plasma TG levels gradually
decreased in WT mice, whereas plasma TG showed a marked
increase in the Angptl4-Tg mice, leading to an almost 24-fold
difference after 24 hours of fasting (Figure 1A). The severe
hypertriglyceridemia in fasted Angptl4-Tg was mainly be-
cause of dramatically elevated plasma VLDL levels, as
determined by fast protein liquid (FPLC), although IDL/LDL
levels were also increased to some extent (Figure 1B). No
difference in HDL-cholesterol levels was observed (Figure
1B). Detailed lipoprotein profiling was performed by gel
permeation high-performance liquid chromatography
(HPLC), which allows for better separation between the
lipoprotein classes (supplemental Table II). In addition to
VLDL, other lipoprotein fractions were also markedly en-
riched in TG. Amazingly, chylomicrons were still detected in
plasma of 24-hour fasted Angptl4-Tg mice (supplemental
Table II), which was visualized as a distinct peak in front of
the VLDL peak (data not shown).
Previously, it was shown that Angptl4 inhibits the activity
of LPL in vitro.13 Using an endogenous LPL activity assay,
we observed a dramatic 90% reduction in post-heparin
plasma LPL activity in 24-hour fasted Angptl4-Tg compared
Figure 1. Severe hypertriglyceridemia in Angptl4-Tg mice. A, Time course of plasma TG during 24-hour fasting in WT mice (gray
squares, n7) and Angptl4-Tg mice (black squares, n10). Error bars reflect SEM. B, Pooled plasma of 24-hour fasted WT mice
(gray squares, n7) and Angptl4-Tg mice (black squares, n10) was analyzed for lipoprotein profiles by FPLC. Elution of molecular
weight markers is indicated.
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with WT mice. Similarly, activity of hepatic lipase (HL) was
about 50% reduced (Figure 2A). In contrast, mRNA levels of
LPL in adipose tissue and of HL in liver were significantly
increased in Angplt4-Tg mice, likely reflecting a mechanism
that attempts to compensate for the decrease in enzyme
activity (Figure 2B). Recent in vitro data suggest that Angptl4
inactivates LPL by promoting the conversion of catalytically
active LPL dimers into inactive monomers.19 This type of
mechanism is expected to cause permanent inactivation of
LPL. To verify whether this is the case, recombinant hAng-
ptl4 was either preincubated with [3H]TO-labeled VLDL-like
emulsion particles followed by mixing with LPL and mea-
surement of LPL activity, or alternatively preincubated with
HSPG-bound LPL and removed by washing before addition
of the VLDL-like particles and measurement of LPL activity.
Whereas the first assay revealed an expected potent inhibition
Figure 2. Angptl4 inhibits lipoprotein lipase activity by promoting formation of LPL monomers. A, Endogenous post-heparin plasma HL
and LPL activity in 24-hour fasted mice (n8 per group). B, mRNA expression of HL and LPL in liver and WAT, respectively. Errors
bars represent SEM. n7 to 10 mice per group. Statistical significance according to Student t test. *P0.05; **P0.01; ***P0.001.
C, Left panel: Effect of Angptl4 on LPL activity in solubilized LPL assay. Amount of [3H]FFA released at increasing concentrations of
hAngptl4 is expressed as a percentage of control treatment. Right panel: Effect of Angptl4 on LPL activity in HSPG-bound LPL assay.
D, Post-heparin plasma from 24-hour fasted WT and Angptl4-Tg mice was applied to a heparin sepharose column and eluted with a
NaCl gradient in the presence of BSA. Fractions were analyzed for LPL by ELISA. E, Pre-heparin plasma from 24-hour fasted WT and
Angptl4-Tg mice was applied to a heparin sepharose column and eluted with a NaCl gradient in the absence of BSA. Fractions were
analyzed for LPL and Angptl4 by Western blot. Upper panel: NaCl concentration in fractions. F, Pooled plasma of 24-hour fasted WT
mice was fractionated by FPLC. Fractions corresponding to VLDL, LDL, and HDL were analyzed for LPL or Angplt4 protein by Western
blot. Molecular weight markers (in kDa) are shown.
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of LPL activity by Angptl4 (Figure 2C, left panel), a similar
effect was observed in the second assay (right panel), sug-
gesting that Angptl4 may permanently disable LPL. Because
LPL monomers have much lower affinity for HSPG than LPL
dimers, an Angptl4-mediated LPL27 dimer to monomer con-
version would be expected to translate into a decrease in LPL
dimers in Angptl4-Tg mice in post-heparin plasma, and
possibly an increase in LPL monomers in pre-heparin plasma.
To visualize LPL monomers and dimers, pre- and post-
heparin plasma from 24-hour fasted WT and Angptl4-Tg
mice was separated by heparin-sepharose affinity chromatog-
raphy and fractions assayed for LPL content.19 Importantly, a
marked decrease in LPL dimer content was observed in
post-heparin plasma of Angptl4-Tg mice (Figure 2D). No
LPL was detected in fractions from pre-heparin plasma by
ELISA (detection limit 0.2 ng/150 L). However, using a
more sensitive Western blot assay LPL protein was detected
in fractions corresponding to LPL monomer in Angptl4-Tg
but not WT mice (Figure 2E). These data indicate that
Angptl4 overexpression promotes the conversion of endothe-
lial-bound LPL dimers into circulating LPL monomers.
To investigate whether Angptl4 might physically associate
with circulating LPL monomers, we studied the coelution of
Angptl4 and LPL in pre-heparin plasma fractions from the
heparin-sepharose column and gel filtration FPLC column. It
was observed that Angptl4, present in the truncated form, was
present in exactly the same heparin-sepharose fractions as
monomeric LPL (Figure 2E). The same observation was
made in the FPLC fractions: Angptl4 was present in the
fractions corresponding to (large) LDL (Figure 2F), which
also harbors monomeric LPL, as previously published.28
These data suggest that in blood plasma Angptl4 is physically
associated with LDL-bound LPL monomers.
To examine whether inhibition of LPL by Angptl4 over-
expression resulted in a decrease in LPL-dependent
VLDL-TG lipolysis, the decay of protein-free VLDL-like
emulsion particles labeled with glycerol tri[3H]oleate
([3H]TO) and [14C]cholesteryl oleate ([14C]CO) was moni-
tored in fed and 24-hour fasted WT and Angptl4-Tg mice. In
the fed state, no difference in the clearance of [3H]TO was
observed between the 2 genotypes (Figure 3A; serum half life
274.5 minutes versus 32.25.2 minutes, respectively). In
contrast, in the 24-hour fasted state, clearance of [3H]TO was
much lower in Angptl4-Tg mice, as evidenced by an almost
8-fold increase in serum half-life (1029.3 minutes versus
13.82.6 minutes, respectively; P0.01). In fact, whereas in
WT mice fasting accelerated [3H]TO clearance, the opposite
was true in Angptl4-Tg mice. This was supported by mea-
surement of tissue uptake of [3H]TO-derived [3H]oleate,
which was markedly reduced in heart, liver, skeletal muscle,
and adipose tissues of 24-hour fasted Angptl4-Tg mice in
comparison with WT mice (Figure 3C). These data indicate
Figure 3. Serum decay and tissue uptake of radiolabeled VLDL-like emulsion particles. VLDL-like particles labeled with glycerol
tri[3H]oleate and [14C]cholesteryl oleate were injected into anesthetized mice. Serum samples were collected at indicated times and
measured for 3H-activity (A) and 14C-activity (B). After 30 minutes, mice were euthanized and tissues collected for measurement of
3H-activity (C) and for 14C-activity (D) (bottom). Errors bars represent SEM. n4 to 6 mice per group. Differences between WT and
Angptl4-Tg mice were evaluated by Mann–Whitney test. *P0.05; **P0.01.
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that Angptl4 overexpression strongly inhibited LPL-
dependent VLDL-TG lipolysis.
As the VLDL-like emulsion particles also contained
[14C]CO, it was possible to monitor clearance of VLDL-
cholesteryl esters. Similar to the situation for [3H]TO, in WT
mice fasting accelerated [14C]CO clearance, whereas clear-
ance was decelerated in Angptl4-Tg mice (Figure 3B; serum
half life 29.510.4 minutes versus 26224.5 minutes, re-
spectively; P0.01). Tissue uptake of [14C]CO, which occurs
mainly in liver and is secondary to LPL-and HL-mediated
conversion of VLDL to LDL via IDL, was also strongly
reduced in Angptl4-Tg mice (Figure 3D).
To find out whether the decreased hepatic uptake of VLDL
[3H]TO and [14C]CO in Angptl4-Tg mice was paralleled by
changes in liver lipids, we measured hepatic cholesterol and
TG content. Whereas in fed state no difference in liver
cholesterol was observed between WT and Angptl4-Tg mice,
in the fasted state liver cholesterol was modestly but signif-
icantly decreased in Angptl4-Tg mice (Figure 4A). In con-
trast, hepatic TG content was not changed significantly in
Angptl4-Tg (supplemental Figure II). In response to the
decrease in hepatic cholesterol uptake and content in the
fasted Angptl4-Tg mice, one would expect marked changes in
the expression of genes dependent on cholesterol. To inves-
tigate the effect of Angptl4 overexpression on hepatic gene
expression, we performed microarray analysis. RNA from
liver of several animals was pooled and hybridized to
Affymetrix mouse genome 430 2.0 GeneChip arrays. Using a
cut-off of 1.4-fold, expression of a total of 103 probe sets was
increased in Angptl4-Tg mice compared with WT mice. Of
the 103 probe sets, 40 probe sets represented genes directly
involved in cholesterol and fatty acid biosynthesis, including
3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) syn-
thase 1, HMG-CoA reductase, and Isopentenyl diphosphate 
isomerase (supplemental Figure III). Upregulation of these
genes in Angptl4-Tg mice was verified by qPCR (Figure 4B
and supplemental Figure IV). The increased expression of
cholesterol biosynthetic enzymes at the mRNA level was
supported by an increase in plasma lathosterol to cholesterol
ratio, which serves as a marker for cholesterol biosynthesis
rate (Figure 4C). Together, these data indicate that in the
24-hour fasted state Angptl4 overexpression causes a marked
reduction in hepatic cholesterol uptake, leading to a decrease
in hepatic cholesterol content and subsequent upregulation of
cholesterol biosynthesis.
Besides major changes in lipid metabolism, Angptl4 over-
expression also caused alterations at the level of glucose
metabolism. Whereas in the fed state no difference in plasma
glucose was observed between WT and Angptl4-Tg mice, in
the 24-hour fasted state Angplt4-Tg mice exhibited a modest
yet significant increase in plasma glucose (Figure 5A). In
contrast, no difference in plasma insulin was observed be-
tween the 2 sets of mice in either fed or fasted state (Figure
5B). These data suggest that Angptl4-Tg mice may be mildly
insulin resistant. To investigate whether this is the case, we
performed a hyperinsulinemic-euglycemic clamp in 24-hour
fasted mice. Under basal conditions, glucose metabolism was
not different between the 2 sets of mice. However, under
hyperinsulinemic conditions glucose use was significantly
decreased in Angptl4-Tg mice compared with WT mice
(Figure 5C). Indeed, whereas in WT mice glucose use
increased by 125% after insulin infusion, in Angptl4-Tg mice
glucose use only went up 59% (Figure 5D). Interestingly,
endogenous glucose production was not affected by insulin
infusion in WT mice, characteristics of the highly insulin-re-
sistant FVB strain, yet was clearly inhibited by insulin in
Angptl4-Tg mice (Figure 5F). These data suggest that
Angptl4-Tg mice are insulin-resistant in the periphery, but
more insulin-sensitive at the hepatic level.
Discussion
In the present article we took advantage of the sensitivity of
our Angptl4 overexpression model to fasting to better char-
acterize the metabolic role of Angptl4. The most dramatic
metabolic abnormality in Angptl4-Tg mice is the fasting-
dependent elevation of plasma TG levels. The severe hyper-
triglyceridemia, with plasma TG levels reaching 20 mmol/L
after 24 hours of fasting, can be attributed to marked
inhibition of LPL-dependent VLDL and chylomicron lipoly-
sis. Accordingly, we provide the definitive in vivo evidence
that the hypertriglyceridemic effect of Angptl4 observed in
several studies is attributable to impaired clearance of plasma
TG via inhibition of LPL-dependent lipolysis of TG-rich
lipoproteins. The inhibition of LPL activity by Angptl4 was
linked to conversion of endothelial-bound catalytically active
Figure 4. Upregulation of hepatic cholesterol synthesis in Angptl4-Tg mice. A, Hepatic cholesterol concentration. B, mRNA expression
of 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1. C, Plasma lathosterol to cholesterol ratio. Errors bars represent SEM. n7 to
16 mice per group. Statistical significance according to Student t test. *P0.05; **P0.01; ***P0.001.
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LPL dimers into circulating catalytically inactive LPL mono-
mers, as previously demonstrated in vitro.19
One major consequence of inhibition of LPL- and HL-
dependent VLDL/IDL lipolysis in Angptl4-Tg mice is a
reduced formation of LDL, leading to a marked decrease in
cholesterol uptake in liver and a subsequent decrease in
hepatic cholesterol content. The decrease in hepatic choles-
terol led to upregulation of almost every single gene that is
part of the cholesterol synthesis pathway. In fact, close to
40% of the genes identified by microarray as being upregu-
lated in livers of Angplt4-Tg mice were involved in either
fatty acid or cholesterol synthesis. Thus, by inhibiting LPL
and HL, Angptl4 has a major impact on cellular cholesterol-
uptake and consequently cholesterol-dependent gene regula-
tion. The changes in gene expression translated into a
functional change in the rate of cholesterol synthesis, as
shown by elevated plasma lathosterol to cholesterol ratio.
We suspect that Angptl4 overexpression may similarly
suppress fatty acid–dependent gene regulation, especially in
tissues that rely heavily on LPL for fatty acid uptake. Fatty
acid-dependent gene regulation is mainly mediated by
PPARs. Previous studies have indicated that LPL can act on
circulating lipoproteins to generate endogenous PPAR li-
gands, thus providing a potentially important link between
lipoprotein metabolism and transcriptional effects of PPAR.29
Indeed, it was shown that cardiac-specific knock-out of LPL
resulted in decreased expression of several PPAR target
genes.30 Future studies will have to clarify whether Angptl4
overexpression has any influence on fatty acid and PPAR-
dependent gene regulation in tissues that express LPL.
Recently, it was shown that the N-terminal domain of
Angptl4 (residues 1 to 187) is able to dissociate catalytically
active LPL dimers into catalytically inactive LPL monomers
in vitro, suggesting a novel mechanism for regulating LPL
activity.19 Our data indicate that overexpression of Angptl4 in
mice leads to conversion of endothelial-bound LPL dimers
into circulating LPL monomers. Consequently, in
Angptl4-Tg mice less LPL dimers are released into the
circulation on heparin injection, providing an explanation for
the marked decrease in post-heparin LPL activity. Interest-
ingly, the relative decrease in post-heparin LPL activity
exceeded the relative decrease in heparin-releasable LPL
dimers, suggesting that Angptl4 may inhibit LPL activity via
an additional mechanism. An Angptl4-mediated LPL dimer
to monomer conversion was supported by the presence of
LPL monomers in pre-heparin plasma of Angptl4-Tg mice
but not WT mice. However, the low concentration of LPL
monomers suggests that they are rapidly cleared from the
circulation. Our data also suggest that in blood plasma
Angptl4 is physically associated with LPL monomers, which
in turn are bound to LDL. It can be hypothesized that by
binding LPL monomers, Angptl4 pulls the equilibrium be-
tween LPL dimers and monomers toward monomers, which
effectively results in an inhibition of LPL activity. This model
conflicts with the mechanism proposed by Sukonina et al
based on experiments carried out in vitro.19 More research is
necessary to elucidate the precise mechanism by which
Angptl4 promotes conversion of LPL dimers to monomers in
vivo.
In addition to inhibition of LPL activity, we also observed
that Angptl4 overexpression resulted in a significant decrease
in post-heparin plasma HL activity, although the effect was
less pronounced compared with LPL. Inhibition of HL may
contribute to the elevated levels of IDL/LDL, especially the
increase in IDL/LDL-TG content, and likely contributes to
the observed decrease in hepatic cholesterol uptake. The latter
result could also be linked to increased IDL/LDL-particle
size, which has been shown to lead to reduced hepatic uptake
via a mechanism independent of the LDL receptor.24
In line with the role of HL in converting HDL2 to HDL3,
inhibition of HL may contribute to the elevated HDL-TG
content in Angptl4-Tg mice. Similar to LPL, HL is function-
ally active as a dimer.31,32 Accordingly, it is possible that
inhibition of HL activity by Angplt4 is accounted for by
conversion of HL dimers to monomers. In contrast to our
observations, Koster et al did not observe any change in
post-heparin plasma HL activity in mice with liver-specific
Angptl4 overexpression or in Angptl4 KO mice.17 The reason
for this discrepancy is not clear but may be related to
differences in the sensitivity of the HL activity assay used or
to differences in the magnitude of Angptl4 overexpression.
Figure 5. Peripheral insulin resistance in fasted Angptl4-Tg
mice. Plasma glucose (A) and insulin (B) levels in fed and
24-hour fasted WT and Angptl4-Tg mice. n7 to 10 mice per
group. A hyperinsulinemic euglycemic clamp was carried out in
24-hour fasted WT and Angptl4-Tg mice. C, Whole body glu-
cose use under basal and hyperinsulinemic conditions. D, Per-
centage induction of glucose use by insulin. E, Endogenous glu-
cose production (EGP) under basal and hyperinsulinemic
conditions. F, Percentage inhibition of EGP by insulin. Errors
bars represent SEM. n3 to 6 mice per group. Statistical signifi-
cance according to Student t test. *P0.05; **P0.01.
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In contrast to HDL-TG, HDL-Chol levels were identical
between the 2 sets of mice. Although LPL activity and
HDL-Chol levels are positively correlated in humans, no link
between LPL activity and HDL-Chol levels has been ob-
served in mice overexpressing LPL or in LPL null mice,
which is probably explained by the absence of CETP activity
in mice.33 Recently, it was reported that Angptl3, which is
structurally and functionally highly related to Angptl4, inhib-
its activity of endothelial lipase, an important determinant of
HDL-Chol levels.34 Mice lacking Angptl3 showed a decrease
in plasma HDL-Chol and HDL phospholipid, coupled with
increased phospholipase activity in post-heparin plasma.
Furthermore, Angptl3 inhibited the phospholipase activity of
endothelial lipase in vitro. Whether Angptl4 may inhibit
endothelial lipase as well remains to be investigated.
Whereas the impact of Angptl4 on plasma lipoprotein
metabolism is well established, much less is known about the
role of Angptl4 in glucose homeostasis. Recently it was
reported that adenoviral-mediated overexpression of Angplt4
causes an abrupt and dramatic decrease in plasma glucose
coupled to a marked improvement in glucose tolerance.16 In
contrast to the hypertriglyceridemia elicited by Angptl4
overexpression, which was transient, the hypoglycemia was
persistent up to 2 weeks after virus injection when plasma
levels of Angptl4 had almost returned to normal. Infection of
primary hepatocytes with Angptl4 adenovirus significantly
decreased secretion of glucose into the medium, suggesting
that Angptl4 may lower plasma glucose by decreasing hepatic
glucose output. In partial support of this notion, we find
decreased endogenous glucose production in Angptl4-Tg
mice under hyperinsulinemic conditions, whereas no change
was found under basal conditions. At the same time, Angptl4
overexpression was associated with a decrease in insulin-
mediated glucose disposal, suggesting peripheral insulin re-
sistance. Under conditions of prolonged fasting, the effect of
Angptl4 on peripheral insulin resistance seems to dominate as
plasma glucose was modestly increased in Angptl4-Tg mice
compared with WT mice, whereas plasma insulin levels
remained unaltered. The decreased peripheral insulin sensi-
tivity in Angptl4-Tg mice may be related to elevated plasma
FFA, which are known to induce insulin resistance,35 al-
though a direct effect of Angptl4 protein on insulin signaling
cannot be excluded. In mice, the overall impact of Angptl4 on
plasma glucose levels appears to be limited, and may only be
evident at higher plasma Angptl4 concentrations because
inactivation of the Angptl4 did not result in any change in
plasma glucose.17 However, this observation does not exclude
an effect of Angptl4 inactivation on glucose fluxes. It was
reported that in humans, levels of Angptl4 in blood plasma of
obese diabetics are significantly decreased in comparison
with obese nondiabetics.16 Although these data still have to be
verified, they suggest that in humans Angptl4 might serve as
a marker for insulin sensitivity.
Whereas the effects of Angptl4 on lipoprotein metabolism
in mice are supported by numerous studies, much less is
known about the role of Angptl4 in humans. Recently, it was
shown that a variant of the human Angptl4 gene (E40K),
which is present in approximately 3% of European Ameri-
cans, was associated with significantly lower plasma TG
levels and higher HDL-Chol levels.36 These data suggest that,
at least with respect to plasma TG, the effect of Angptl4 is
similar between mice and humans. The picture is a little bit
more complicated for HDL-Chol. Previously, we found a
positive correlation between plasma Angptl4 concentration,
assessed semiquantitatively by immunoblot, and HDL-Chol
levels.23 In the present study, no change in plasma HDL-Chol
level was observed in Angptl4-Tg mice, despite a 20-fold
increase in plasma TG. Thus, the link between Angptl4 and
HDL, and the impact of Angptl4 on effectors of plasma HDL
levels, deserve further study.
In conclusion, we show that (1) the hypertriglyceridemic
effect of Angptl4 is attributable to inhibition of LPL-
dependent VLDL lipolysis by converting endothelial-bound
LPL dimers to circulating LPL monomers, (2) Angptl4
upregulates cholesterol synthesis in liver via inhibition of
LPL- and HL-dependent hepatic cholesterol uptake, and (3)
Angptl4 overexpression increases insulin sensitivity in liver
but decreases insulin sensitivity in the periphery.
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SUPPLEMENTAL METHODS 
 
Animal experiments. The Angptl4-transgenic mice on FVB background have been previously 
described 18. Only male mice were used. Animals were kept in standard cages with food and 
water ad libitum. Animals were fed normal laboratory chow (RMH-B 2181, Arie Blok animal 
feed, Woerden, the Netherlands), containing 23.5% protein, 5% fat, 38.3% starch, and 4% 
sugar. Mice in fed state were sacrificed at the beginning of the light cycle. Mice in fasted state 
were deprived of food for 24 hours starting at the beginning of the light cycle. At the time of 
sacrifice animals were between 2 and 4 months of age. Blood was collected via orbital 
puncture into EDTA tubes. After sacrificing the mice by cervical dislocation, tissues were 
excised and immediately frozen in liquid nitrogen. All animal experiments were approved by 
the animal experimentation committee of Wageningen University. 
 
Plasma metabolites. Blood was collected into paraoxon-coated capillaries to prevent ongoing 
in vitro lipolysis. Blood samples were placed on ice and centrifuged at 4°C for 10 minutes at 
10,000 g. The plasma glucose concentration was determined using a kit from Elitech 
(Sopachem, Wageningen, Netherlands). Plasma and tissue TG and plasma glycerol 
concentrations were determined using kits from Instruchemie (Delfzijl, Netherlands). Plasma 
free fatty acids were determined using a kit from WAKO Chemicals (Sopachem, 
Wageningen, Netherlands). Plasma ketones (β-hydroxybutyrate) were determined using 
Precision Xtra (Abbott laboratories, Bedford, MA, USA). plasma lathosterol was determined 
by capillary gas chromatography. Plasma insulin was determined using a kit from Linco (St. 
Charles, MO, USA). 
 
Liver cholesterol. Liver cholesterol content was determined as previously described 20. 
Briefly, a ~100 mg liver samples was saponified by heating in ethanol-KOH, and cholesterol 
was extracted from the saponified solution with hexane. After evaporation of hexane, 
cholesterol was derivatized to trimethylesters using bis-silyl-tri-fluor-aceetamide. Cholesterol 
was subsequently quantified by gas chromatography. 
 
Lipoprotein profiling. Plasma lipoproteins of wild-type and Angptl4-Tg mice were separated 
using fast protein liquid chromatography (FPLC). 0.2 mL of pooled plasma was injected into 
a Superose 6B 10/300 column (GE Healthcare Bio-Sciences AB, Roosendaal, Netherlands) 
and eluted at a constant flow of 0.5 mL/minute with phosphate buffered saline (pH 7.4). The 
effluent was collected in 0.5 mL fractions and TG and cholesterol levels were determined 
(Instruchemie). Separation of lipoproteins by gel permeation HPLC was performed as a 
lipoprotein analysis service by LipoSEARCH (Tokyo, Japan) using 10 µL of pooled plasma. 
 
Modulated plasma LPL and HL activity assay. 24 hour fasted mice were injected via the tail 
vein with heparin (0.1U/g; Leo Pharmaceutical Products B.V., Weesp, Netherlands) and 
blood was collected after 10 min. The plasma was snap-frozen and stored at -80°C until 
analysis of LPL and hepatic lipase (HL) activity as previously described 21. 
 
In vitro LPL activity assay. The effect of recombinant hAngptl4 (residues 26-229, hAngptl-
S2) (Biovendor Laboratory Medicine, Modrice, Czech Republic) on LPL-dependent TG 
hydrolysis of [3H]TO-VLDL-like emulsion particles was determined as described (solubilized 
LPL assay) 4. A HSPG-bound LPL assay was performed by first coating plates with HSPG 
(250 ng/well), followed by coating with LPL (0.2 U/well). HSPG-bound LPL was 
subsequently pre-incubated with recombinant hAngptl4 for 30 min at 37ºC, washed three 
times with 100 mM Tris-HCl pH 8.5, followed by addition of [3H]TO-VLDL-like emulsion 
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particles. After 15 minutes incubation, the reaction was terminated and lipids extracted as 
described4. The amount of [3H]FFA released was measured by scintillation counting and 
expressed as a percentage of [3H]FFA released in the absence of Angptl4. 
 
Heparin-Sepharose Chromatography. Heparin-sepharose chromatography was carried out on 
a Pharmacia FPLC system. A HiTrap Heparin HP 1 mL column (GE Healthcare Bio-Sciences 
AB, Roosendaal, Netherlands) was equilibrated with 0.25M NaCl/20% glycerol/1% BSA/10 
mM sodium phosphate pH6.5. Pre- and post-heparin plasma was adjusted to the concentration 
of the equilibration buffer before loading. After loading the equivalent of 0.2 ml mouse blood 
plasma, the column was washed (10mL), followed by elution with a linear gradient of NaCl 
(from 0.25 to 1.5 M) in equilibration buffer at a flow rate of 0.5 ml/minute. BSA was omitted 
when fractions were intended for analysis by Western blot.  Murine LPL in fractions was 
measured by enzyme-linked immunosorbent assay 22. 
 
Isolation of total RNA and Q-PCR. Extraction of RNA, cDNA synthesis and quantitative 
PCR were carried out as previously described 18.  
 
Western blot. Fractions collected of the HiTrap HP-column or Superose 6B column were 
separated by SDS-PAGE and transferred to Immobilon-P membrane (Millipore, Bedford, 
MA, USA). Western blotting was carried out as described previously 10, 23. The LPL primary 
antibody (anti-mouse LPL CA1787, Cell Applications Inc., San Diego, CA, USA) was used at 
1:500, and the secondary antibody (HRP-labelled anti-rabbit IgG, Sigma) at 1:4000. All 
incubations were performed in Tris-buffered saline, pH 7.5, with 0.1% Tween-20 and 5% dry 
milk, except for the final washings when dry milk was omitted. 
 
Preparation of VLDL-like Emulsion Particles. TG-rich VLDL-like emulsion particles (80 
nm) were prepared as described 24. Radiolabeled emulsions were obtained by adding 200 µCi 
of glycerol tri[3H]oleate (triolein, TO) and 20 µCi of [14C]cholesteryl oleate (CO) to 100 mg 
of emulsion lipids before sonication. 
 
In Vivo Clearance of VLDL-Like Emulsion Particles. Mice were anesthetized with 
hypnorm(fentanyl)/midazolam and injected with the radiolabeled emulsion particles (1.0 mg 
TG in 200 µl PBS) at 8:00 a.m. into the tail vein. At indicated time points after injection, 
blood was taken from the tail vein to determine the serum decay of [3H]TO and [14C]CO by 
scintillation counting (Packard Instruments, Dowers Grove, IL, USA). At 30 min after 
injection, mice were sacrified by cervical dislocation and tissues were collected. Tissues were 
weighed and dissolved overnight in Solvable (Packard Bioscience, Meriden, CT, USA), 
followed by measurement of 3H- and 14C-activities in Ultima Gold (Packard Bioscience). The 
total plasma volumes of the mice were calculated from the equation V (ml) = 0.04706 x body 
weight (g), as determined from 125I-BSA clearance studies as previously described 25. 
 
Microarray. RNA was prepared from livers of 24h fasted wild-type and Angptl4-Tg mice 
using Trizol and subsequently pooled per group (n=7). Pooled RNA was further purified 
using Qiagen RNeasy columns and the quality verified by lab on a chip analysis (Bioanalyzer 
2100, Agilent, Amsterdam, Netherlands). 10 µg of RNA was used for one cycle of cRNA 
synthesis (Affymetrix, Santa Clara, USA). Hybridization, washing and scanning of 
Affymetrix Genechip mouse genome 430 2.0 arrays was according to standard Affymetrix 
protocols. Fluorimetric data were processed by Affymetrix GeneChip Operating software and 
the gene chips were globally scaled to all the probe sets with an identical target intensity value 
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using MAS5.0 algorithm. Further analysis was performed by Data Mining Tool (Affymetrix). 
Only probe sets labeled present in both wild-type and Angptl4-Tg mice were considered. 
 
Hyperinsulinemic euglycemic clamp analysis. Wild-type and Angptl4-Tg mice were fasted 
for 24 hours prior to the clamp studies. The hyperinsulinemic euglycemic clamp and assays 
for blood glucose and plasma insulin were carried out as previously described 26.  
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 Supplemental Table I:Plasma parameters. FFA, glycerol, ketones bodies and TG 
concentrations were determined in EDTA plasma of fed and 24h fasted WT and Angptl4-Tg 
mice. Values are mean±SEM. n=7-10 mice/group. Statistical significance according to 





Supplemental Table II: Lipoprotein cholesterol and TG content. Pooled plasma of 24h 
fasted wild-type and Angptl4-Tg mice was separated by gel permeation HPLC using 
lipoprotein analysis service by LipoSEARCH. CM, chylomicron. Concentrations are 







Supplemental Figure I: Marked over-expression of Angptl4 mRNA in 24h fasted Angptl4-
Tg mice. Angptl4 mRNA expression in liver, heart, white adipose tissue (WAT), skeletal 
muscle, and brown adipose tissue (BAT) of fed and 24h fasted WT (grey bars) and Angptl4-
Tg (black bars) mice. Errors bars represent SEM. n=5-10 mice/group.  Statistical significance 
according to Student’s t test. **, p< 0.01; ***, p< 0.001. 
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Supplemental Figure II: No significant change in hepatic triglycerides in Angptl4-Tg mice. 
Hepatic triglyceride concentration in fed and 24h fasted WT and Angptl4-Tg mice. Similar 





Supplemental Figure III: Upregulation of genes involved in hepatic cholesterol synthesis 
in Angptl4-Tg mice. Microarray analysis was performed on pooled livers (n=7) of 24h fasted 
WT and Angptl4-Tg mice. The threshold for fold-induction was set at 1.4. Approximately 
40% of the probe sets upregulated in Angptl4-Tg mice represented genes involved in 
cholesterol synthesis or lipogenesis. 
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Supplemental Figure IV: Upregulation of genes involved in hepatic cholesterol synthesis 
in Angptl4-Tg mice. mRNA expression of two genes involved in cholesterol synthesis was 
measured by real-time quantitative PCR. Errors bars represent SEM. n=7-10 mice/group. 
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